filename,arm_name,intervention_type,screening_window,1_month,3_months,6_months,9_months,12_months,core_treatment_screening_window,core_treatment_1_month,core_treatment_3_months,core_treatment_6_months,core_treatment_9_months,core_treatment_12_months,imaging_diagnostics_screening_window,imaging_diagnostics_1_month,imaging_diagnostics_3_months,imaging_diagnostics_6_months,imaging_diagnostics_9_months,imaging_diagnostics_12_months,labs_screening_window,labs_1_month,labs_3_months,labs_6_months,labs_9_months,labs_12_months,clinic_visits_screening_window,clinic_visits_1_month,clinic_visits_3_months,clinic_visits_6_months,clinic_visits_9_months,clinic_visits_12_months,cycle_length_days,treatment_duration_rule,visit_pattern,assumptions
23358972,FOLFIRI + sunitinib (Arm A),intervention,1,4,8,16,24,32,0,3,6,12,18,24,1,1,2,4,6,8,0,0,0,0,0,0,0,0,0,0,0,0,42,until progression,"Screening, C1D1, C1D8, C1D15, C1D22, C1D29, C2D1, etc.","Screening visit counted as 1 contact day (Day -28 to Day -1); FOLFIRI administered every 2 weeks (3 courses per 6-week cycle); Sunitinib administered daily for 4 weeks followed by 2 weeks off; Tumor imaging performed every 6 weeks; Physical exams and labs performed on Day 1 of each cycle; Mid-cycle visits (Day 8, 15, 22, 29) counted as separate contact days when in-person assessments are required"
23358972,FOLFIRI + placebo (Arm B),control,1,4,8,16,24,32,0,3,6,12,18,24,1,1,2,4,6,8,0,0,0,0,0,0,0,0,0,0,0,0,42,until progression,"Screening, C1D1, C1D8, C1D15, C1D22, C1D29, C2D1, etc.","Screening visit counted as 1 contact day (Day -28 to Day -1); FOLFIRI administered every 2 weeks (3 courses per 6-week cycle); Placebo administered daily for 4 weeks followed by 2 weeks off; Tumor imaging performed every 6 weeks; Physical exams and labs performed on Day 1 of each cycle; Mid-cycle visits (Day 8, 15, 22, 29) counted as separate contact days when in-person assessments are required"
23940216,cediranib 30 mg monotherapy,intervention,1,5,10,20,30,40,0,5,10,20,30,40,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening, C1D1, C1D7, C1D14, C1D21, C1D28, C1D35, then every 3 weeks (C2D1, C3D1, etc.)","Screening visit counted as 1 contact day; Weekly visits for first 6 weeks (Days 1, 7, 14, 21, 28, 35) counted as 5 visits in 1 month window; Subsequent visits every 3 weeks counted through Day +365; All visits assumed to include core treatment administration; MRI assessments not counted as separate contact days if performed on same day as treatment visits"
23940216,cediranib 20 mg + lomustine,intervention,1,6,12,24,36,48,0,6,12,24,36,48,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening, C1D1, C1D7, C1D14, C1D21, C1D28, C1D35, then every 3 weeks (C2D1, C3D1, etc.)","Screening visit counted as 1 contact day; Weekly visits for first 6 weeks (Days 1, 7, 14, 21, 28, 35) counted as 6 visits in 1 month window (additional visit for lomustine administration); Subsequent visits every 3 weeks counted through Day +365; All visits assumed to include core treatment administration; MRI assessments not counted as separate contact days if performed on same day as treatment visits"
23940216,lomustine + cediranib matched placebo,control,1,6,12,24,36,48,0,6,12,24,36,48,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening, C1D1, C1D7, C1D14, C1D21, C1D28, C1D35, then every 3 weeks (C2D1, C3D1, etc.)","Screening visit counted as 1 contact day; Weekly visits for first 6 weeks (Days 1, 7, 14, 21, 28, 35) counted as 6 visits in 1 month window (additional visit for lomustine administration); Subsequent visits every 3 weeks counted through Day +365; All visits assumed to include core treatment administration; MRI assessments not counted as separate contact days if performed on same day as treatment visits"
27264120,Letrozole 2.5 mg/day x 5 years,intervention,1,1,1,2,2,3,0,1,1,1,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,1,1,1,1,30,5 years or until progression,"Screening, Month 1 (telephone), Month 6 (clinic + labs), Month 12 (clinic + labs + mammogram)","Telephone contact at 1 month counts as a clinic visit day; Mammogram at 12 months counts as imaging diagnostics day; Range visits (e.g., Day 14-21) counted as single visit on earliest day; All lab draws assumed to require in-person visit"
27264120,Placebo daily x 5 years,control,1,1,1,2,2,3,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,1,1,1,1,1,1,30,5 years or until progression,Identical to intervention arm minus treatment administration days,Same visit schedule as intervention arm for monitoring purposes; Placebo administration not counted as healthcare contact day; All safety monitoring visits identical between arms per protocol design
27569442,MAP (Good Responders),control,2,4,8,12,12,12,0,4,8,12,12,12,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,29 weeks total,"Screening, Baseline, C1D1, C1D8, C2D1, C2D8, Surgery (Week 11), C3D1, C3D8, C4D1, C4D8, C5D1, C5D8, C6D1, C6D8",Screening and baseline assessments occur over 2 separate days; MAP cycles are 3 weeks duration based on standard osteosarcoma protocols; Treatment continues for total 29 weeks as stated in protocol summary; Surgical resection at Week 11 counts as 1 healthcare contact day; Standard imaging and lab monitoring assumed at baseline
27569442,MAPifn (Good Responders),intervention,2,4,8,12,18,24,0,4,8,12,18,24,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,104 weeks total,"Screening, Baseline, MAP cycles (C1D1, C1D8, C2D1, C2D8, Surgery, C3D1, C3D8, C4D1, C4D8, C5D1, C5D8, C6D1, C6D8) + weekly interferon visits from Week 30-104",Screening and baseline assessments occur over 2 separate days; MAP cycles are 3 weeks duration; Pegylated interferon maintenance continues weekly for 104 weeks total; Interferon administration requires weekly in-person visits; Surgical resection at Week 11 counts as 1 healthcare contact day; Standard imaging and lab monitoring assumed at baseline
27569442,MAP (Poor Responders),control,2,4,8,12,12,12,0,4,8,12,12,12,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,29 weeks total,"Screening, Baseline, C1D1, C1D8, C2D1, C2D8, Surgery (Week 11), C3D1, C3D8, C4D1, C4D8, C5D1, C5D8, C6D1, C6D8",Screening and baseline assessments occur over 2 separate days; MAP cycles are 3 weeks duration; Treatment continues for total 29 weeks as stated; Surgical resection at Week 11 counts as 1 healthcare contact day; Standard imaging and lab monitoring assumed at baseline
27569442,MAPIE (Poor Responders),intervention,2,4,8,16,20,20,0,4,8,16,20,20,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,40 weeks total,"Screening, Baseline, MAP cycles (C1D1, C1D8, C2D1, C2D8, Surgery) + MAPIE cycles with additional treatment days through Week 40","Screening and baseline assessments occur over 2 separate days; MAP cycles are 3 weeks duration, MAPIE cycles may vary; MAPIE treatment continues for total 40 weeks as stated; Surgical resection at Week 11 counts as 1 healthcare contact day; MAPIE regimen involves more intensive scheduling with additional treatment days; Standard imaging and lab monitoring assumed at baseline"
31821109,Chemotherapy alone (TC regimen),control,2,2,6,12,18,20,0,2,6,6,6,6,0,0,0,1,1,1,1,0,0,1,7,9,1,0,0,4,4,4,21,6 cycles (approximately 18 weeks),"Screening (2 visits), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, then quarterly follow-up visits","TC regimen: 6 cycles of docetaxel + cyclophosphamide every 3 weeks; Cycle length = 21 days based on 'every 3 weeks' terminology; Treatment visits occur on Day 1 of each cycle; Imaging assumed at baseline, 6, 12 months per standard adjuvant breast cancer follow-up; Lab monitoring assumed at baseline, 6, 12 months plus additional monitoring during active treatment; Clinic visits assumed quarterly during follow-up period after chemotherapy completion"
31821109,Chemotherapy alone (AC→WP regimen),control,2,9,21,25,29,33,0,9,21,16,12,12,0,0,0,1,1,1,1,0,0,4,12,16,1,0,0,4,4,4,21,4 cycles AC + 12 weeks paclitaxel (approximately 24 weeks),"Screening (2 visits), AC cycles: C1D1, C2D1, C3D1, C4D1, then 12 weekly paclitaxel visits, then quarterly follow-up","AC→WP regimen: 4 cycles AC (every 2-3 weeks) + 12 weekly paclitaxel doses; Used conservative 3-week cycle for AC based on protocol flexibility; Weekly paclitaxel = 12 consecutive weekly visits; Imaging at baseline, 6, 12 months per standard follow-up; More frequent lab monitoring during intensive weekly chemotherapy phase; Quarterly clinic visits during follow-up period"
31821109,Chemotherapy plus trastuzumab (TC + H regimen),intervention,2,2,6,13,20,27,0,2,6,13,20,27,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,21,Chemotherapy: 6 cycles; Trastuzumab: 1 year total,"Screening (2 visits), then every-3-week visits for chemotherapy and trastuzumab through 1 year",TC + H: 6 cycles chemo every 3 weeks + trastuzumab continues every 3 weeks for 1 year total; Trastuzumab given concurrently with chemo and continues post-chemo; 17 total trastuzumab doses (1 year = 52 weeks ÷ 3 = ~17 cycles); Imaging/labs/clinic visits consolidated with treatment visits when possible; All contact days during treatment period are core_treatment due to drug administration
31821109,Chemotherapy plus trastuzumab (AC→WP + H regimen),intervention,2,9,21,29,37,45,0,9,21,29,37,45,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,21,Chemotherapy: 4 cycles AC + 12 weeks paclitaxel; Trastuzumab: 1 year total,"Screening (2 visits), AC cycles, 12 weekly visits (paclitaxel + trastuzumab), then Q3W trastuzumab through 1 year","AC→WP + H: 4 cycles AC + 12 weekly paclitaxel with weekly trastuzumab, then Q3W trastuzumab to complete 1 year; Weekly trastuzumab during paclitaxel phase, then Q3W for remainder of year; Total trastuzumab: 12 weekly + ~13 Q3W doses = ~25 total doses; All monitoring consolidated with treatment visits; Higher contact burden due to weekly schedule during paclitaxel phase"
34087126,Daratumumab plus pomalidomide and dexamethasone (DaraPomDex),intervention,2,5,13,25,37,49,0,4,12,24,36,48,0,0,0,0,0,0,2,1,1,1,1,1,0,0,0,0,0,0,28,until progression,"Screening, Randomization (C1D1), C1D8, C1D15, C1D22, C2D1, C2D8, C2D15, C2D22, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15, then every 4 weeks (C7D1, C8D1, etc.)","Screening and randomization are separate in-person visits; Daratumumab administration schedule: weekly for 8 weeks (Cycles 1-2), then every 2 weeks for 16 weeks (Cycles 3-6), then every 4 weeks thereafter; Pomalidomide is oral self-administered at home (not counted as contact day); Dexamethasone is oral self-administered at home (not counted as contact day); Treatment continues until progression, assumed through 12 months for calculation; No mandatory mid-cycle in-person assessments beyond drug administration; All daratumumab infusions require in-person healthcare contact"
34087126,Pomalidomide and dexamethasone (PomDex),control,2,1,3,6,9,12,0,0,0,0,0,0,0,0,0,0,0,0,2,1,3,6,9,12,0,0,0,0,0,0,28,until progression,"Screening, Randomization (C1D1), C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1","Screening and randomization are separate in-person visits; Pomalidomide is oral self-administered at home (not counted as contact day); Dexamethasone is oral self-administered at home (not counted as contact day); Treatment continues until progression, assumed through 12 months for calculation; Only cycle Day 1 visits require in-person attendance for lab monitoring; No mandatory mid-cycle in-person assessments; No drug administration requiring in-person contact"
34110925,Reduced-dose craniospinal radiation (18 Gy) + Smaller volume boost,intervention,2,9,17,29,41,53,0,7,13,23,33,43,1,1,2,3,4,5,1,1,2,3,4,5,0,0,0,0,0,0,28,fixed 9 cycles of maintenance chemotherapy,"Screening, Randomization, Radiation Phase (30 days over 6 weeks), 4-week rest, Maintenance Cycles 1-9 (alternating 6-week/4-week cycles)","Screening and randomization are separate in-person visits; Radiation therapy occurs daily Monday-Friday (5 days/week) for 6 weeks; Weekly vincristine during radiation (6 doses) given on radiation days; Maintenance chemotherapy cycles alternate 6-week and 4-week regimens for 9 cycles total; Each maintenance cycle includes at least 1 in-person visit for chemotherapy administration; Imaging and lab assessments occur at key timepoints (baseline, post-radiation, during maintenance); All participants receive same treatment structure regardless of randomization arm"
34110925,Reduced-dose craniospinal radiation (18 Gy) + Standard volume boost,intervention,2,9,17,29,41,53,0,7,13,23,33,43,1,1,2,3,4,5,1,1,2,3,4,5,0,0,0,0,0,0,28,fixed 9 cycles of maintenance chemotherapy,"Screening, Randomization, Radiation Phase (30 days over 6 weeks), 4-week rest, Maintenance Cycles 1-9 (alternating 6-week/4-week cycles)","Screening and randomization are separate in-person visits; Radiation therapy occurs daily Monday-Friday (5 days/week) for 6 weeks; Weekly vincristine during radiation (6 doses) given on radiation days; Maintenance chemotherapy cycles alternate 6-week and 4-week regimens for 9 cycles total; Each maintenance cycle includes at least 1 in-person visit for chemotherapy administration; Imaging and lab assessments occur at key timepoints (baseline, post-radiation, during maintenance); Boost volume randomization does not affect number of contact days"
34110925,Standard-dose craniospinal radiation (23.4 Gy) + Smaller volume boost,control,2,9,17,29,41,53,0,7,13,23,33,43,1,1,2,3,4,5,1,1,2,3,4,5,0,0,0,0,0,0,28,fixed 9 cycles of maintenance chemotherapy,"Screening, Randomization, Radiation Phase (30 days over 6 weeks), 4-week rest, Maintenance Cycles 1-9 (alternating 6-week/4-week cycles)","Screening and randomization are separate in-person visits; Radiation therapy occurs daily Monday-Friday (5 days/week) for 6 weeks; Weekly vincristine during radiation (6 doses) given on radiation days; Maintenance chemotherapy cycles alternate 6-week and 4-week regimens for 9 cycles total; Each maintenance cycle includes at least 1 in-person visit for chemotherapy administration; Imaging and lab assessments occur at key timepoints (baseline, post-radiation, during maintenance); Craniospinal radiation dose randomization does not affect number of contact days"
34110925,Standard-dose craniospinal radiation (23.4 Gy) + Standard volume boost,control,2,9,17,29,41,53,0,7,13,23,33,43,1,1,2,3,4,5,1,1,2,3,4,5,0,0,0,0,0,0,28,fixed 9 cycles of maintenance chemotherapy,"Screening, Randomization, Radiation Phase (30 days over 6 weeks), 4-week rest, Maintenance Cycles 1-9 (alternating 6-week/4-week cycles)","Screening and randomization are separate in-person visits; Radiation therapy occurs daily Monday-Friday (5 days/week) for 6 weeks; Weekly vincristine during radiation (6 doses) given on radiation days; Maintenance chemotherapy cycles alternate 6-week and 4-week regimens for 9 cycles total; Each maintenance cycle includes at least 1 in-person visit for chemotherapy administration; Imaging and lab assessments occur at key timepoints (baseline, post-radiation, during maintenance); Both randomizations do not affect number of contact days"
34874182,Arm A: Palbociclib + Standard Adjuvant Endocrine Therapy,intervention,2,2,4,8,12,16,0,1,2,4,6,8,0,0,1,2,3,4,1,1,1,2,3,4,1,0,0,0,0,0,28,2 years palbociclib + at least 5 years endocrine therapy,"Screening, Baseline, C1D1, C1D14-21, C2D1, C2D14-21, ... continuing through C13D1, C13D14-21 (for 12 months)","Standard Schedule of Events assumed with screening visit, baseline visit, then Day 1 of each 28-day cycle; Palbociclib administered as 21 days on/7 days off per cycle; Mid-cycle visits assumed for safety monitoring on Day 14-21 of each cycle; Imaging (CT/MRI) performed every 3 months (12 weeks); Lab monitoring performed monthly for first 3 months, then every 3 months; Endocrine therapy continues beyond palbociclib completion but requires fewer visits"
34874182,Arm B: Standard Adjuvant Endocrine Therapy Alone,control,2,1,2,3,4,5,0,0,0,0,0,0,0,0,1,1,2,2,1,1,1,2,2,3,1,0,0,0,0,0,0,at least 5 years endocrine therapy,"Screening, Baseline, Month 3, Month 6, Month 9, Month 12",Standard endocrine therapy follow-up schedule with less frequent monitoring; Imaging performed every 6 months instead of every 3 months; Lab monitoring quarterly after initial baseline; No drug-specific safety monitoring visits required; Primarily follow-up and monitoring visits rather than active treatment visits
35660812,Arm A (RVD only),,3,5,12,22,32,42,0,3,8,14,20,26,1,1,2,4,6,8,2,1,2,4,6,8,0,0,0,0,0,0,21,until progression,"Initial RVD cycles (21-day), PBSC collection, additional RVD cycles, then monthly maintenance",Cycle length is 21 days based on 'RVD q 21 days' specification; PBSC collection involves 2-3 in-person visits (counted as 3 days); Maintenance lenalidomide requires monthly in-person visits for assessment and prescription; Standard monitoring visits include labs and imaging at key timepoints; Treatment continues until progression per protocol
35660812,Arm B (RVD + auto SCT),,3,8,18,28,38,48,0,6,12,18,24,30,1,1,3,5,7,9,2,1,3,5,7,9,0,0,0,0,0,0,21,until progression,"Initial RVD, PBSC collection, transplant hospitalization, additional RVD, then monthly maintenance",Cycle length is 21 days for RVD treatment phases; Transplant procedure involves intensive hospitalization period (7-10 days counted); Melphalan infusion over 2 days requires separate contact days; PBSC collection and reinfusion require multiple in-person visits; Additional monitoring required post-transplant increases contact frequency; Maintenance continues monthly until progression
35704479,Treatment Arm,intervention,2,1,1,2,3,4,0,1,1,1,2,3,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,180,until progression or study completion,"Screening (2 visits), Baseline Treatment (Day 0), 6-month follow-up, 12-month follow-up with potential additional treatment sessions",Screening requires 2 visits: one for initial screening/consent and one for biopsy-proven HSIL confirmation; Treatment occurs at baseline (Day 0) and may require additional sessions; Follow-up occurs every 6 months with HRA and potential re-treatment; Conservative estimate: 1 treatment session per 6-month period with additional visits for assessment; Assumed treatment modalities may require multiple sessions but used conservative single-session estimates
35704479,Active Monitoring Arm,control,2,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,2,180,monitoring only until study completion,"Screening (2 visits), 6-month follow-up, 12-month follow-up",Screening requires 2 visits: one for initial screening/consent and one for biopsy-proven HSIL confirmation; Active monitoring involves HRA and assessment every 6 months; No treatment interventions occur in this arm; 12-month visit includes comprehensive assessment similar to screening
35728048,Azacitidine,control,2,8,24,48,72,96,0,7,21,42,63,84,0,0,1,2,3,4,1,1,2,4,6,8,1,0,0,0,0,0,28,until progression,"Screening, Randomization, C1D1-5, C1D8, C1D9, C2D1-5, C2D8, C2D9, ... CkD1-5, CkD8, CkD9 + q3mo bone marrow assessments","Screening and Randomization are separate in-person visits; Azacitidine administration on Days 1-5, 8, 9 = 7 treatment days per cycle; Bone marrow assessments every 3 months (Days 90, 180, 270, 365); Treatment continues until progression through Day 365; Cycle 1 includes 7 treatment days, subsequent cycles same pattern; No mid-cycle assessments requiring additional visits"
35728048,Pevonedistat Plus Azacitidine,intervention,2,8,24,48,72,96,0,7,21,42,63,84,0,0,1,2,3,4,1,1,2,4,6,8,1,0,0,0,0,0,28,until progression,"Screening, Randomization, C1D1-5, C1D8, C1D9, C2D1-5, C2D8, C2D9, ... CkD1-5, CkD8, CkD9 + q3mo bone marrow assessments","Screening and Randomization are separate in-person visits; Pevonedistat on Days 1,3,5 and Azacitidine on Days 1-5,8,9 = 7 treatment days per cycle (drugs given same days when overlapping); Bone marrow assessments every 3 months (Days 90, 180, 270, 365); Treatment continues until progression through Day 365; Cycle 1 includes 7 treatment days, subsequent cycles same pattern; No mid-cycle assessments requiring additional visits"
35759733,REGIMEN I: CT-2103 135mg/m² q 28-days x 12,intervention,1,1,3,6,9,12,0,1,3,6,9,12,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,12 cycles (fixed duration),"Screening (Day -28 to -1), then C1D1, C2D1, C3D1...C12D1","Screening visit includes required laboratory testing (CA-125, etc.) counted as 1 contact day; Each monthly cycle involves one in-person infusion visit (10-20 minute infusion); No mid-cycle visits specified - only Day 1 of each 28-day cycle; Treatment duration fixed at 12 cycles regardless of progression status; No additional imaging or diagnostic visits specified beyond screening"
35759733,REGIMEN II: Paclitaxel 135mg/m² q 28-days x 12,intervention,1,1,3,6,9,12,0,1,3,6,9,12,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,12 cycles (fixed duration),"Screening (Day -28 to -1), then C1D1, C2D1, C3D1...C12D1","Screening visit includes required laboratory testing (CA-125, etc.) counted as 1 contact day; Each monthly cycle involves one in-person infusion visit (3-hour infusion); No mid-cycle visits specified - only Day 1 of each 28-day cycle; Treatment duration fixed at 12 cycles regardless of progression status; No additional imaging or diagnostic visits specified beyond screening"
35759733,REGIMEN III: No further treatment until evidence of disease progression,control,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,no treatment until progression,Screening (Day -28 to -1) only,"Screening visit includes required laboratory testing (CA-125, etc.) counted as 1 contact day; No active treatment visits - only monitoring for disease progression; No scheduled follow-up visits specified in the provided protocol pages; Patients followed until progression but no routine contact days specified"
35763704,Atezolizumab + ddAC-PacHP,intervention,2,5,13,26,39,52,0,4,12,24,36,48,1,1,1,2,3,4,1,0,0,0,0,0,0,0,0,0,0,0,14,fixed 22 cycles (52 weeks),"Screening, Randomization, C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1, C19D1, C20D1, C21D1, C22D1 plus imaging assessments","Screening and Randomization are separate in-person visits (Day -28 and Day -1); Cycle 1-4: Q2W dosing (every 14 days) with in-person visits on Day 1 of each cycle; Cycle 5-8: Q3W dosing (every 21 days) with in-person visits on Day 1 of each cycle; Cycle 9-22: Q3W dosing (every 21 days) with in-person visits on Day 1 of each cycle; Imaging assessments assumed at screening, end of neoadjuvant phase (Cycle 8), surgery, and quarterly during adjuvant phase; Baseline labs assumed during screening visit; All treatment administration requires in-person healthcare contact"
35763704,Placebo + ddAC-PacHP,control,2,5,13,26,39,52,0,4,12,24,36,48,1,1,1,2,3,4,1,0,0,0,0,0,0,0,0,0,0,0,14,fixed 22 cycles (52 weeks),"Screening, Randomization, C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1, C15D1, C16D1, C17D1, C18D1, C19D1, C20D1, C21D1, C22D1 plus imaging assessments","Screening and Randomization are separate in-person visits (Day -28 and Day -1); Cycle 1-4: Q2W dosing (every 14 days) with in-person visits on Day 1 of each cycle; Cycle 5-8: Q3W dosing (every 21 days) with in-person visits on Day 1 of each cycle; Cycle 9-22: Q3W dosing (every 21 days) with in-person visits on Day 1 of each cycle; Imaging assessments assumed at screening, end of neoadjuvant phase (Cycle 8), surgery, and quarterly during adjuvant phase; Baseline labs assumed during screening visit; All treatment administration requires in-person healthcare contact; Placebo administration follows same schedule as atezolizumab"
35922251,Cemiplimab (REGN2810),,2,3,6,12,18,24,,,,,,,,,,,,,,,,,,,,,,,,,,,,
35922251,Investigator's Choice Chemotherapy,,2,4,8,16,24,32,,,,,,,,,,,,,,,,,,,,,,,,,,,,
35947817,DCC-2618,intervention,2,2,6,12,18,24,0,1,3,6,9,12,1,1,3,6,9,12,1,0,0,0,0,0,0,0,0,0,0,0,42,until progression (up to 2 years),"Screening (2 visits), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1 with imaging every 2 cycles",6-week cycle length (42 days) based on protocol description; Continuous daily dosing for DCC-2618 means no additional in-person visits beyond cycle starts; Baseline imaging required within 21 days prior to first dose (counted in screening window); Standard oncology monitoring schedule assumed: imaging every 2 cycles (every 12 weeks); Screening includes at least 2 visits: initial screening and baseline assessments
35947817,Sunitinib,control,2,2,6,12,18,24,0,1,3,6,9,12,1,1,3,6,9,12,1,0,0,0,0,0,0,0,0,0,0,0,42,until progression (up to 2 years),"Screening (2 visits), C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1 with imaging every 2 cycles","6-week cycle length (42 days) with 4 weeks on, 2 weeks off schedule; Cycle start visits only for treatment administration and monitoring; Baseline imaging required within 21 days prior to first dose (counted in screening window); Standard oncology monitoring schedule assumed: imaging every 2 cycles (every 12 weeks); Screening includes at least 2 visits: initial screening and baseline assessments; No additional in-person visits during treatment weeks beyond cycle starts"
36099926,atezolizumab,intervention,2,2,4,8,12,16,0,1,3,6,9,12,1,0,0,1,1,2,0,0,0,0,1,1,1,1,1,1,1,1,21,"16 cycles or 1 year, whichever occurs first","Screening, Baseline, then q3w treatment visits (C1D1, C2D1...C16D1) with imaging every 3 months",Screening and baseline visits are separate in-person days; Treatment visits occur every 3 weeks (21 days) for up to 16 cycles or 1 year; Imaging occurs every 3 months for first 3 years - counted within time windows; Standard monitoring visits assumed for safety assessments; Treatment continues through Day 365 for contact day calculation
36099926,placebo,control,2,2,4,8,12,16,0,1,3,6,9,12,1,0,0,1,1,2,0,0,0,0,1,1,1,1,1,1,1,1,21,"16 cycles or 1 year, whichever occurs first","Screening, Baseline, then q3w treatment visits (C1D1, C2D1...C16D1) with imaging every 3 months",Placebo administration follows same schedule as active treatment; Screening and baseline visits are separate in-person days; Treatment visits occur every 3 weeks (21 days) for up to 16 cycles or 1 year; Imaging occurs every 3 months for first 3 years - counted within time windows; Standard monitoring visits assumed for safety assessments; Treatment continues through Day 365 for contact day calculation
30516102,Trastuzumab emtansine,intervention,2,3,7,13,19,25,0,2,5,9,13,17,1,1,1,2,3,4,1,0,1,2,3,4,0,0,0,0,0,0,21,14 cycles (fixed duration),"Screening, Randomization, then C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1",Standard q3w (21-day cycle) schedule with treatment on Day 1 of each cycle; 14 cycles total as specified in protocol; Screening includes at least 2 in-person visits (screening assessments + randomization); Standard oncology monitoring includes baseline imaging and periodic imaging assessments; Treatment continues through Day 273 (Cycle 13 Day 1) with final treatment on Day 273
30516102,Trastuzumab,control,2,3,7,13,19,25,0,2,5,9,13,17,1,1,1,2,3,4,1,0,1,2,3,4,0,0,0,0,0,0,21,14 cycles (fixed duration),"Screening, Randomization, then C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, C13D1, C14D1",Standard q3w (21-day cycle) schedule with treatment on Day 1 of each cycle; 14 cycles total as specified in protocol; Screening includes at least 2 in-person visits (screening assessments + randomization); Standard oncology monitoring includes baseline imaging and periodic imaging assessments; Treatment continues through Day 273 (Cycle 13 Day 1) with final treatment on Day 273; Both arms have identical visit schedules per protocol description
31327689,Arm A,intervention,2,5,15,30,45,60,0,5,15,30,45,60,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening, Randomization, then weekly visits on days 1, 8, 15, 22 of each 28-day cycle + Q3W pembrolizumab visits aligned with cycle day 1 visits","Screening phase includes 2 in-person visits (screening and randomization) based on standard trial design; Pembrolizumab Q3W visits occur on C1D1, C2D1, C3D1, etc. (every 21 days from Day 0); Lenalidomide/dexamethasone weekly visits occur on days 1, 8, 15, 22 of each 28-day cycle; Treatment continues until progression (assumed beyond 12 months for calculation); Weekly dexamethasone visits (days 1, 8, 15, 22) are considered core_treatment days; Screening visits categorized as labs based on typical screening procedures"
31327689,Arm B,control,2,4,12,24,36,48,0,4,12,24,36,48,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening, Randomization, then weekly visits on days 1, 8, 15, 22 of each 28-day cycle","Screening phase includes 2 in-person visits (screening and randomization) based on standard trial design; Lenalidomide/dexamethasone weekly visits occur on days 1, 8, 15, 22 of each 28-day cycle; Treatment continues until progression (assumed beyond 12 months for calculation); Weekly dexamethasone visits (days 1, 8, 15, 22) are considered core_treatment days; Screening visits categorized as labs based on typical screening procedures; No additional pembrolizumab visits in control arm"
35665782,Trastuzumab deruxtecan (T-DXd),intervention,2,2,6,12,18,24,0,1,3,6,9,12,0,0,1,2,3,4,1,1,2,4,6,8,1,0,0,0,0,0,21,until progression,"Screening, Randomization, then C1D1, C2D1, C3D1... continuing Q3W until progression",T-DXd administered Q3W (every 21 days) based on 'every 3 weeks' dosing schedule; Each cycle includes Day 1 infusion visit only (no mid-cycle visits specified); Imaging occurs every 9 weeks (every 3 cycles) based on standard oncology trial practice; Labs drawn at screening and every cycle (Day 1); Treatment continues until progression per standard oncology trial design; Screening includes separate screening and randomization visits (2 days); No additional in-person assessments beyond Day 1 infusions mentioned
35665782,Treatment of Physician's Choice (TPC),control,2,4,12,24,36,48,0,3,9,18,27,36,0,0,1,2,3,4,1,1,2,4,6,8,1,0,0,0,0,0,21,until progression,"Screening, Randomization, then more frequent treatment visits (average 2 per 3-week cycle) until progression","TPC regimens assumed to have more frequent dosing than T-DXd (weekly or more frequent); Based on standard schedules: Capecitabine (daily oral, but weekly clinic visits), Eribulin (Days 1+8 Q3W), Gemcitabine (Days 1+8+15 Q4W), Paclitaxel (weekly), Nab-paclitaxel (Days 1+8+15 Q3W); Conservative estimate: average of 2 in-person treatment days per 3-week period; Imaging frequency same as T-DXd arm (every 9 weeks); Labs drawn weekly with treatment visits; Treatment continues until progression; Screening includes separate screening and randomization visits (2 days)"
36108662,Pembrolizumab,intervention,2,2,6,12,18,19,0,1,3,6,9,9,0,0,1,2,3,4,1,1,2,4,6,6,1,0,0,0,0,0,21,18 infusions over approximately 12 months,"Screening, Randomization, C1D1, C2D1, C3D1, C4D1+imaging, C5D1, C6D1, C7D1, C8D1+imaging, C9D1, C10D1, C11D1, C12D1+imaging, C13D1, C14D1, C15D1, C16D1+imaging, C17D1+EOT","Standard Q3W (21-day cycle) schedule with treatment on Day 1 of each cycle; 18 total infusions over approximately 12 months (17 cycles); Baseline assessments require 2 separate in-person visits (screening + randomization); Imaging occurs every 12 weeks (cycles 4, 8, 12, 16, and end of treatment); Labs required at screening, Day 1 of each cycle, and end of treatment; Treatment continues until completion of 18 infusions regardless of progression"
36108662,Placebo,control,2,2,6,12,18,19,0,1,3,6,9,9,0,0,1,2,3,4,1,1,2,4,6,6,1,0,0,0,0,0,21,18 infusions over approximately 12 months,"Screening, Randomization, C1D1, C2D1, C3D1, C4D1+imaging, C5D1, C6D1, C7D1, C8D1+imaging, C9D1, C10D1, C11D1, C12D1+imaging, C13D1, C14D1, C15D1, C16D1+imaging, C17D1+EOT","Identical schedule to pembrolizumab arm (triple-blinded design); 18 total placebo infusions over approximately 12 months (17 cycles); Baseline assessments require 2 separate in-person visits (screening + randomization); Imaging occurs every 12 weeks (cycles 4, 8, 12, 16, and end of treatment); Labs required at screening, Day 1 of each cycle, and end of treatment; Treatment continues until completion of 18 infusions regardless of progression"
36322844,Bv-AVEPC,intervention,2,4,10,17,17,17,0,2,5,5,5,5,0,1,2,2,2,2,1,1,3,10,10,10,1,0,0,0,0,0,21,5 cycles (105 days),"Screening, Randomization, C1D1, C1D14-21, C2D1, C2D14-21, C3D1, C3D14-21, C4D1, C4D14-21, C5D1, C5D14-21, End-of-treatment PET",Screening and randomization occur on separate days (Day -28 and Day -1); Each 21-day cycle includes Day 1 treatment visit and Day 14-21 mid-cycle assessment visit; PET scans occur at end of Cycle 2 (Day 42) and end of treatment; Response-adapted ISRT (if needed) occurs after completion of chemotherapy; Treatment continues for 5 cycles total (105 days); Mid-cycle visits (Day 14-21) counted as single in-person assessment days
36322844,ABVE-PC,control,2,4,10,17,17,17,0,2,5,5,5,5,0,1,2,2,2,2,1,1,3,10,10,10,1,0,0,0,0,0,21,5 cycles (105 days),"Screening, Randomization, C1D1, C1D14-21, C2D1, C2D14-21, C3D1, C3D14-21, C4D1, C4D14-21, C5D1, C5D14-21, End-of-treatment PET",Screening and randomization occur on separate days (Day -28 and Day -1); Each 21-day cycle includes Day 1 treatment visit and Day 14-21 mid-cycle assessment visit; PET scans occur at end of Cycle 2 (Day 42) and end of treatment; Response-adapted ISRT (if needed) occurs after completion of chemotherapy; Treatment continues for 5 cycles total (105 days); Mid-cycle visits (Day 14-21) counted as single in-person assessment days; Both arms have identical visit schedules despite different drug regimens
36455168,Pembrolizumab plus Best Supportive Care,intervention,2,3,9,18,27,36,0,2,6,12,18,24,1,1,3,6,9,12,1,0,0,0,0,0,0,0,0,0,0,0,21,until progression (max 35 cycles),"Screening, Randomization, then Q3W Day 1 visits for drug administration with Q6W imaging assessments","Screening and Randomization treated as separate in-person visits (2 days); Q3W dosing cycle with Day 1 visits for drug administration; Q6W imaging assessments (every 2 cycles) requiring in-person attendance; Treatment continues until progression with maximum 35 cycles (~2 years); Baseline imaging and labs performed during screening period; Mid-cycle visits not specified - assumed no additional in-person assessments between Day 1 visits; BSC assumed to be provided during scheduled study visits, not requiring additional contact days"
36455168,Placebo plus Best Supportive Care,control,2,3,9,18,27,36,0,2,6,12,18,24,1,1,3,6,9,12,1,0,0,0,0,0,0,0,0,0,0,0,21,until progression (max 35 cycles),"Screening, Randomization, then Q3W Day 1 visits for placebo administration with Q6W imaging assessments","Screening and Randomization treated as separate in-person visits (2 days); Q3W dosing cycle with Day 1 visits for placebo administration; Q6W imaging assessments (every 2 cycles) requiring in-person attendance; Treatment continues until progression with maximum 35 cycles (~2 years); Baseline imaging and labs performed during screening period; Mid-cycle visits not specified - assumed no additional in-person assessments between Day 1 visits; BSC assumed to be provided during scheduled study visits, not requiring additional contact days; Placebo administration follows same visit schedule as active arm (double-blind design)"
36473143,Nivo/Ipi Combo Arm (Arm A),intervention,2,3,7,13,19,25,0,2,5,9,13,17,0,0,1,2,3,4,1,1,1,1,2,3,1,0,0,1,1,1,42,until 24 months from first treatment or progression,"Screening, Randomization, C1D1, C1D15, C2D1, C2D15, C3D1, C3D15, C4D1, C4D15, C5D1, C5D15, C6D1, C6D15, C7D1, C7D15, C8D1, C8D15, C9D1, C9D15, C10D1, C10D15, C11D1, C11D15, C12D1, C12D15, C13D1, C13D15, C14D1, C14D15, C15D1, C15D15, C16D1, C16D15, C17D1, C17D15","Screening and randomization are separate visits (2 days in screening window); Nivolumab administered every 2 weeks, ipilimumab every 6 weeks; Treatment continues for 24 months or until progression; Imaging assessments every 9 weeks (every 3 cycles); Lab assessments at screening and treatment visits; Clinic visits for physical exams and AE assessments at treatment visits"
36473143,EXTREME regimen Arm (Arm B),control,2,5,13,22,22,22,0,4,11,19,19,19,0,0,1,2,2,2,1,1,1,1,1,1,1,0,0,0,0,0,21,6 cycles chemo then cetuximab until progression,"Screening, Randomization, C1D1 (loading dose), C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1, C4D8, C4D15, C5D1, C5D8, C5D15, C6D1, C6D8, C6D15, then weekly cetuximab visits","Screening and randomization are separate visits (2 days in screening window); Cetuximab loading dose (400 mg/m²) on C1D1, then weekly maintenance; Cisplatin/carboplatin + fluorouracil for maximum 6 cycles (every 3 weeks); Fluorouracil administered as 4-day continuous infusion (counted as 1 contact day for administration); Maintenance cetuximab weekly until progression after 6 cycles; Imaging assessments every 9 weeks; Treatment stops after 6 cycles of chemo, only cetuximab continues"
36521097,Arm A: nab-Paclitaxel plus Gemcitabine,intervention,2,9,18,18,18,18,0,9,18,18,18,18,1,1,2,3,4,5,1,0,0,0,0,0,0,0,0,0,0,0,28,fixed 6 cycles,"Screening, Randomization, C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1, C4D8, C4D15, C5D1, C5D8, C5D15, C6D1, C6D8, C6D15","Screening and randomization are separate in-person visits occurring within Day -28 to Day -1; CT scan during screening is counted as imaging diagnostics; Labs during screening are counted as separate contact day; Treatment visits on Days 1, 8, 15 of each 28-day cycle are core_treatment days; Imaging schedule: baseline (screening), then every 8 weeks (Weeks 8, 16, 24), then every 12 weeks (Weeks 36, 48, 60); Treatment duration fixed at 6 cycles (168 days), no treatment beyond 6 months; Imaging continues per protocol schedule through 12 months"
36521097,Arm B: Gemcitabine alone,control,2,9,18,18,18,18,0,9,18,18,18,18,1,1,2,3,4,5,1,0,0,0,0,0,0,0,0,0,0,0,28,fixed 6 cycles,"Screening, Randomization, C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1, C4D8, C4D15, C5D1, C5D8, C5D15, C6D1, C6D8, C6D15","Screening and randomization are separate in-person visits occurring within Day -28 to Day -1; CT scan during screening is counted as imaging diagnostics; Labs during screening are counted as separate contact day; Treatment visits on Days 1, 8, 15 of each 28-day cycle are core_treatment days; Imaging schedule: baseline (screening), then every 8 weeks (Weeks 8, 16, 24), then every 12 weeks (Weeks 36, 48, 60); Treatment duration fixed at 6 cycles (168 days), no treatment beyond 6 months; Imaging continues per protocol schedule through 12 months"
36535566,MK-3475 (pembrolizumab),intervention,2,2,6,12,18,24,0,1,3,6,9,12,1,1,2,4,6,8,1,0,1,2,3,4,0,0,0,0,0,0,21,until progression (max 35 administrations),"Screening (imaging + labs), C1D1, C2D1, C3D1, ... CkD1 with imaging every 3 cycles",Standard Q3W pembrolizumab schedule with imaging every 9 weeks; Screening includes baseline imaging and labs as separate visits; Treatment continues until progression with maximum 35 administrations; Q3W cycle structure with Day 1 visits only (no mid-cycle visits); Baseline imaging and labs counted as separate contact days
36535566,"Investigator's choice chemotherapy (Capecitabine, Gemcitabine, or Docetaxel)",control,2,4,12,24,36,48,0,2,6,12,18,24,1,1,2,4,6,8,1,1,4,8,12,16,0,0,0,0,0,0,7,until progression,"Screening (imaging + labs), Weekly treatment visits with imaging every 6-9 weeks",Chemotherapy regimens assumed to require weekly visits for Gemcitabine/Docetaxel or bi-weekly for Capecitabine monitoring; Conservative estimate of weekly treatment visits for all regimens; Screening includes baseline imaging and labs as separate visits; Treatment continues until progression with regular monitoring; Weekly lab monitoring required for chemotherapy safety
36541957,Ibrutinib + CIT (RICE or RVICI),intervention,2,4,10,16,19,22,0,2,5,8,10,12,1,1,2,4,5,6,1,1,3,4,4,4,0,0,0,0,0,0,28,until progression,"Screening, Randomization, C1D1, C1D14-21, C2D1, C2D14-21, C3D1, C3D14-21, C4D1, C5D1, C6D1, then every 3 months for imaging","Treatment cycles are 28 days based on protocol statement; Screening and Randomization treated as separate in-person visits; Mid-cycle visits (Day 14-21) counted as single contact day per cycle; Ibrutinib monotherapy continues for 3 cycles after initial 3 cycles of combination therapy; Imaging assessments (CT/MRI) scheduled at screening, end of cycles 3 and 6, then every 3 months; All subjects continue treatment until progression per protocol"
36541957,CIT alone (RICE or RVICI),control,2,3,7,10,10,10,0,2,4,6,6,6,1,0,1,2,2,2,1,1,2,2,2,2,0,0,0,0,0,0,28,3 cycles (84 days),"Screening, Randomization, C1D1, C1D14-21, C2D1, C2D14-21, C3D1, C3D14-21, then imaging follow-ups","Treatment cycles are 28 days based on protocol statement; Screening and Randomization treated as separate in-person visits; Mid-cycle visits (Day 14-21) counted as single contact day per cycle; Control arm receives only 3 cycles of CIT therapy (no monotherapy continuation); Imaging assessments scheduled at screening, end of cycle 3, then every 3 months; Control arm treatment duration limited to 3 cycles unless otherwise specified"
36669140,Regimen A (VDC/IE),control,2,6,18,36,54,72,0,6,18,36,54,72,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,14,fixed duration through consolidation phase,"Screening (2 visits), Induction cycles 1-6 (2 visits/cycle), Consolidation cycles 1-8 (2 visits/cycle)","Screening includes 2 in-person visits: initial screening and randomization/baseline assessments; Induction phase: 6 cycles over 12 weeks, assuming 2 in-person treatment days per cycle (VDC and IE alternating); Consolidation phase: 8 cycles over 16 weeks, assuming 2 in-person treatment days per cycle; Treatment continues through all phases without interruption; Local control and metastatic site irradiation assumed to occur during treatment phases and are included in core_treatment counts; No maintenance phase for Regimen A"
36669140,Regimen B (VDC/IE plus ganitumab),intervention,2,6,18,36,36,36,0,6,18,36,36,36,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,14,fixed duration through consolidation phase (ganitumab maintenance discontinued),"Screening (2 visits), Induction cycles 1-6 (2 visits/cycle), Consolidation cycles 1-8 (2 visits/cycle)","Screening includes 2 in-person visits: initial screening and randomization/baseline assessments; Induction phase: 6 cycles over 12 weeks, assuming 2 in-person treatment days per cycle; Consolidation phase: 8 cycles over 16 weeks, assuming 2 in-person treatment days per cycle; Ganitumab was discontinued for all patients as of March 20, 2019, so maintenance phase not counted; Treatment stops after consolidation and metastatic site irradiation (no maintenance); Local control and metastatic site irradiation assumed to occur during treatment phases"
36308441,PledOx (5 µmol/kg) + mFOLFOX6 chemotherapy,intervention,2,3,8,12,12,12,0,3,8,12,12,12,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,14,up to 6 months (12 cycles),"Screening, Randomization, then C1D1, C2D1, C3D1, ..., C12D1 (one visit per 14-day cycle)",Standard mFOLFOX6 regimen with 14-day cycles (12 cycles over 6 months); Screening includes separate screening and randomization visits (2 days); Each cycle requires one in-person visit for IMP administration and mFOLFOX6 infusion; Treatment duration capped at 6 months (12 cycles) as per protocol indication; No mid-cycle visits specified in provided protocol text; Screening assessments include baseline imaging and labs requiring in-person attendance
36308441,Placebo + mFOLFOX6 chemotherapy,control,2,3,8,12,12,12,0,3,8,12,12,12,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,14,up to 6 months (12 cycles),"Screening, Randomization, then C1D1, C2D1, C3D1, ..., C12D1 (one visit per 14-day cycle)",Standard mFOLFOX6 regimen with 14-day cycles (12 cycles over 6 months); Screening includes separate screening and randomization visits (2 days); Each cycle requires one in-person visit for placebo administration and mFOLFOX6 infusion; Treatment duration capped at 6 months (12 cycles) as per protocol indication; No mid-cycle visits specified in provided protocol text; Screening assessments include baseline imaging and labs requiring in-person attendance
36327426,Durvalumab + Tremelimumab + SoC Chemotherapy,intervention,2,4,8,16,24,32,0,2,4,8,12,16,1,1,2,4,6,8,1,1,2,4,6,8,0,0,0,0,0,0,21,until progression,"Screening, Randomization, C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1, C4D8, C4D15, then q4w durvalumab maintenance visits","Standard q3w chemotherapy cycle length (21 days) applied; SoC chemotherapy given for 4 cycles as stated in protocol; Durvalumab maintenance given q4w (28-day cycles) until progression; Baseline assessments split between Screening and Randomization visits; Tumor imaging assumed at baseline, every 6 weeks during chemo, then every 8 weeks during maintenance; Lab assessments assumed at each treatment visit and mid-cycle during chemotherapy"
36327426,Durvalumab + SoC Chemotherapy,intervention,2,4,8,16,24,32,0,2,4,8,12,16,1,1,2,4,6,8,1,1,2,4,6,8,0,0,0,0,0,0,21,until progression,"Screening, Randomization, C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1, C4D8, C4D15, then q4w durvalumab maintenance visits","Standard q3w chemotherapy cycle length (21 days) applied; SoC chemotherapy given for 4 cycles as stated in protocol; Durvalumab maintenance given q4w (28-day cycles) until progression; Baseline assessments split between Screening and Randomization visits; Tumor imaging assumed at baseline, every 6 weeks during chemo, then every 8 weeks during maintenance; Lab assessments assumed at each treatment visit and mid-cycle during chemotherapy"
36327426,SoC Chemotherapy,control,2,4,8,12,16,20,0,2,4,6,8,10,1,1,2,3,4,5,1,1,2,3,4,5,0,0,0,0,0,0,21,4-6 cycles,"Screening, Randomization, C1D1, C1D8, C1D15, C2D1, C2D8, C2D15, C3D1, C3D8, C3D15, C4D1, C4D8, C4D15, C5D1, C5D8, C5D15","Standard q3w chemotherapy cycle length (21 days) applied; SoC chemotherapy given for 4-6 cycles as stated in protocol (assumed 5 cycles average); No maintenance therapy after chemotherapy completion; Baseline assessments split between Screening and Randomization visits; Tumor imaging assumed at baseline, every 6 weeks during chemo, then less frequently after completion; Lab assessments assumed at each treatment visit and mid-cycle during chemotherapy"
36346687,Capecitabine,intervention,2,4,8,16,16,16,0,2,4,8,8,8,0,0,0,0,0,0,2,2,4,8,8,8,0,0,0,0,0,0,21,8 cycles (168 days),"Screening, Randomization, C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C7D1, C8D1","Screening and randomization are separate in-person visits requiring assessments; Cycle 1 Day 1 is Day 0 (anchor point); Each 21-day cycle includes Day 1 visit for drug administration and assessment; Treatment duration is exactly 8 cycles (168 days) as specified; No mid-cycle visits mentioned, only Day 1 per cycle; No imaging or additional clinic visits specified beyond treatment administration"
36346687,Observation,control,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,no active treatment,"Screening, Randomization only",Screening and randomization are separate in-person visits requiring assessments; Observation arm has no scheduled treatment visits after randomization; No follow-up visits specified in the provided protocol text; Only screening/randomization assessments count as healthcare contact days
36395435,Zanubrutinib 160 mg orally twice daily,intervention,2,3,7,13,19,25,0,1,3,6,9,12,1,1,2,3,4,5,1,1,2,4,6,8,0,0,0,0,0,0,28,until progression,"Screening, Randomization, C1D1, C2D1, C3D1, C4D1 (+CT), C5D1, C6D1, C7D1 (+CT), continuing every 28 days with CT scans every 3 cycles","Screening and Randomization are separate in-person visits (2 days); CT scans performed at Screening, Cycle 4, then every 3 cycles for 25 cycles, then every 6 cycles; Cycle 1 Day 1 is Day 0 (treatment start); Each cycle is 28 days as specified; Treatment continues until progression (assumed beyond 12 months for calculation); Physical exams, lab assessments, and safety monitoring occur at each in-person visit; Bone marrow exams only performed for potential CR/CRi cases (not counted as routine); All visits include required in-person assessments (vitals, physical exam, labs)"
36395435,Ibrutinib 420 mg orally once daily,control,2,3,7,13,19,25,0,1,3,6,9,12,1,1,2,3,4,5,1,1,2,4,6,8,0,0,0,0,0,0,28,until progression,"Screening, Randomization, C1D1, C2D1, C3D1, C4D1 (+CT), C5D1, C6D1, C7D1 (+CT), continuing every 28 days with CT scans every 3 cycles","Screening and Randomization are separate in-person visits (2 days); CT scans performed at Screening, Cycle 4, then every 3 cycles for 25 cycles, then every 6 cycles; Cycle 1 Day 1 is Day 0 (treatment start); Each cycle is 28 days as specified; Treatment continues until progression (assumed beyond 12 months for calculation); Physical exams, lab assessments, and safety monitoring occur at each in-person visit; Bone marrow exams only performed for potential CR/CRi cases (not counted as routine); All visits include required in-person assessments (vitals, physical exam, labs)"
36503738,BBI-608 plus biweekly FOLFIRI (Arm 1),intervention,2,4,8,14,20,26,0,2,4,7,10,13,0,1,2,4,5,7,1,1,2,3,5,6,1,0,0,0,0,0,14,until progression,"Screening, Randomization, then C1D1, C2D1, C3D1, etc. every 14 days + tumor assessment visits","Cycle length is 14 days as stated in protocol; Treatment continues until progression (365 days assumed for calculation); Screening and Randomization are separate in-person visits; Tumor assessments every 8 weeks until 6 months, then every 12 weeks; BBI-608 pre-treatment days (2-5 days before C1D1) are not counted as they are oral and self-administered; Mid-cycle assessments are not mentioned, so only Day 1 visits per cycle are counted"
36503738,biweekly FOLFIRI alone (Arm 2),control,2,3,7,13,19,25,0,2,4,7,10,13,0,1,2,4,5,7,1,0,1,2,4,5,1,0,0,0,0,0,14,until progression,"Screening, Randomization, then C1D1, C2D1, C3D1, etc. every 14 days + tumor assessment visits","Cycle length is 14 days as stated in protocol; Treatment continues until progression (365 days assumed for calculation); Screening and Randomization are separate in-person visits; Tumor assessments every 8 weeks until 6 months, then every 12 weeks; No BBI-608 pre-treatment for this arm; Mid-cycle assessments are not mentioned, so only Day 1 visits per cycle are counted"
36764316,AMG 510 (sotorasib),intervention,2,2,6,12,18,24,0,1,3,6,9,12,1,0,1,2,3,4,1,1,2,4,6,8,0,0,0,0,0,0,28,until progression,"Screening, Baseline, then C1D1, C2D1, C3D1, etc. every 28 days with imaging every 3 cycles","Standard oncology trial visit pattern assumed: screening visit + baseline visit, then Day 1 of each cycle; Cycle length for AMG 510 assumed to be 28 days (once daily oral dosing); Treatment continues until progression per protocol; Imaging assumed every 9 weeks (approximately every 3 cycles); Labs assumed every cycle on Day 1; Safety follow-up visit at 30 days after last dose not counted in 12-month window"
36764316,docetaxel,control,2,2,6,10,14,18,0,1,3,5,7,9,1,0,1,2,3,4,1,1,2,3,4,5,0,0,0,0,0,0,21,until progression,"Screening, Baseline, then C1D1, C2D1, C3D1, etc. every 21 days with imaging every 3 cycles",Standard docetaxel schedule: 75 mg/m² IV every 3 weeks; Cycle length for docetaxel is 21 days; Treatment continues until progression per protocol; Imaging assumed every 9 weeks (approximately every 3 cycles); Labs assumed every cycle on Day 1; Safety follow-up visit at 30 days after last dose not counted in 12-month window; Fewer cycles than AMG 510 due to 21-day vs 28-day cycle length
36795891,Rucaparib,intervention,2,2,6,12,18,24,0,2,6,12,18,24,1,0,1,2,3,4,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (baseline imaging + labs), then imaging assessments at Weeks 8, 16, 24, 36, 48, etc.","Screening includes baseline imaging (CT/MRI + bone scan) and baseline blood draw as separate contact days; Rucaparib is oral medication taken at home - no routine in-person administration; Tumor assessments every 8 weeks for first 24 weeks, then every 12 weeks thereafter; Treatment continues until progression; No routine in-person visits beyond screening and imaging assessments specified; Imaging assessments require separate healthcare facility visits"
36795891,Physician's Choice (Docetaxel or AR-directed therapy),control,2,5,13,25,37,49,0,5,13,25,37,49,1,0,1,2,3,4,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (baseline imaging + labs), then monthly clinic visits for monitoring + imaging assessments at Weeks 8, 16, 24, 36, 48, etc.","Screening includes baseline imaging (CT/MRI + bone scan) and baseline blood draw as separate contact days; Docetaxel administered every 3 weeks (21-day cycles) with in-person infusion visits; AR-directed therapies (abiraterone/enzalutamide) are oral but require regular monitoring visits; Assuming physician's choice follows standard monitoring schedules with monthly clinic visits; Tumor assessments every 8 weeks for first 24 weeks, then every 12 weeks thereafter; Treatment continues until progression; Imaging assessments require separate healthcare facility visits"
